Advertisement

FDA Approves New Drug for Two Types of Pulmonary Hypertension — Physician’s First Watch

Medical News |
October 10, 2013

FDA Approves New Drug for Two Types of Pulmonary Hypertension

By Kristin J. Kelley

Riociguat (marketed as Adempas) has been approved to improve exercise capacity in adults with chronic thromboembolic pulmonary hypertension after surgery and pulmonary arterial hypertension of unknown origin.

Approval for the drug — a soluble guanylate cyclase stimulator that decreases blood pressure and increases blood flow — was based on two randomized trials of some 700 patients. In both studies, patients who received riociguat could walk at least 36 meters farther in 6 minutes than those on placebo after 12 to 16 weeks of treatment.

Common treatment side effects include diarrhea, dizziness, dyspepsia, headache, nausea, peripheral edema, and vomiting.

Reader Comments (1)

Stan Van Uum Physician, Endocrinology, London, Ontario

LIke this way of keeping up to date!

Your Comment

(will not be published)

Filtered HTML

  • Allowed HTML tags: <a> <em> <strong> <cite> <blockquote> <code> <ul> <ol> <li> <dl> <dt> <dd>
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Do you have any conflict of interest to disclose?
CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.
Image CAPTCHA
Enter the characters shown in the image.

Vertical Tabs

* Required

Reader comments are intended to encourage lively discussion of clinical topics with your peers in the medical community. We ask that you keep your remarks to a reasonable length, and we reserve the right to withhold publication of remarks that do not meet this standard.

PRIVACY: We will not use your email address, submitted for a comment, for any other purpose nor sell, rent, or share your e-mail address with any third parties. Please see our Privacy Policy.

Advertisement
Advertisement
Advertisement